1. Introduction {#sec1-ijerph-16-01356}
===============

There is increasing evidence indicating that tobacco use causes several fatal diseases and also contributes to psychological problems \[[@B1-ijerph-16-01356],[@B2-ijerph-16-01356]\]. Similarly, various psychiatric disorders had been reported to be associated with secondhand smoke (SHS) by cotinine and other tobacco-specific biomarkers \[[@B3-ijerph-16-01356],[@B4-ijerph-16-01356]\]. It has well established that nicotine has impacts on the psychophysiological pathways through activating nicotinic acetylcholine receptors and causing intensive expression of nicotinic receptors in the central nervous system \[[@B3-ijerph-16-01356]\], which is associated with psychiatric disorders. In addition, scientific evidence has unequivocally established that inhaling SHS causes disease and death, and there is no risk-free level of SHS exposure \[[@B5-ijerph-16-01356],[@B6-ijerph-16-01356]\]. It is conceivable that high levels of SHS exposure may cause or worsen psychological symptoms (e.g., anxiety and depressive disorders) as a result. Based on these results, we hypothesized that there may be a potential association between SHS exposure and depressive symptoms.

A significant body of studies have demonstrated the effects of SHS on the incidence of depressive symptoms \[[@B7-ijerph-16-01356],[@B8-ijerph-16-01356],[@B9-ijerph-16-01356],[@B10-ijerph-16-01356]\]. Some of them reported significantly positive associations \[[@B7-ijerph-16-01356],[@B8-ijerph-16-01356]\], while other studies revealed non-significant associations \[[@B9-ijerph-16-01356],[@B10-ijerph-16-01356]\], indicating potential inconsistent results. So far only one meta-analysis reported that SHS exposure was significantly associated with depressive symptoms (OR = 1.60), but this study did not provide the information of dose--response association \[[@B11-ijerph-16-01356]\]. Therefore, it is still not clear whether there was a dose--response relationship between SHS exposure and depressive symptoms. In the present study, we performed a systematic search of observational studies on this issue, and then carried out dose--response meta-analyses to explore the potential dose--response relationship between SHS exposure and depressive symptoms.

2. Method {#sec2-ijerph-16-01356}
=========

2.1. Search Strategy {#sec2dot1-ijerph-16-01356}
--------------------

The meta-analysis was conducted following the guidelines of preferred reporting items for systematic reviews and meta-analyses \[[@B12-ijerph-16-01356]\]. Studies were identified through a systematic literature search in the PUBMED and EMBASE electronic databases. The search details were conducted as follows: {"tobacco smoke pollution"(MeSH Terms) OR ("tobacco"(All Fields) AND "smoke"(All Fields) AND "pollution"(All Fields)) OR "tobacco smoke pollution"(All Fields) OR ("secondhand"(All Fields) AND "smoke"(All Fields)) OR "secondhand smoke"(All Fields)} AND {"depression"(MeSH Terms) OR "depression"(All Fields) OR ("depressive"(All Fields) AND "symptoms"(All Fields)) OR "depressive symptoms"(All Fields)}. In addition, reference lists of all the identified papers were reviewed for further eligible publications.

2.2. Inclusion and Exclusion Criteria {#sec2dot2-ijerph-16-01356}
-------------------------------------

Two investigators (CL Han and YQ Liu) independently reviewed and assessed the eligibility of the identified studies using the following inclusion and exclusion criteria. The inclusion criteria required studies to: (1) use depressive symptoms as the outcome and use SHS as the exposure; (2) provide information assessing the association between SHS exposure and depressive symptoms; and (3) report original data including odds ratios (ORs) or relative risks (RRs) with corresponding 95% confidence internal (CI) (or information allowing us to compute them). Studies were excluded if they were not published as full reports, such as conference abstracts and letters to editors. When multiple reports were published on the same study population or subpopulation, only the most recent and informative study that met the inclusion criteria was included. Any discrepancies on whether an article merited inclusion between investigators were resolved by a consensus meeting of the three authors (CL Han, YQ Liu, and XH Ye).

2.3. Data Extraction {#sec2dot3-ijerph-16-01356}
--------------------

Two investigators (CL Han and YQ Liu) extracted data independently using a standardized form and then cross-checked the data together. Disagreements were resolved by consensus. For each study, the following characteristics were collected: first author's name, publication year, geographical region, study design, age, sex, number of participants, diagnosis method of depressive symptoms, definition of SHS exposure, adjustment variables, and the adjusted ORs or RRs with their corresponding 95% CIs for the relation between SHS exposure and depressive symptoms.

2.4. Study Variables {#sec2dot4-ijerph-16-01356}
--------------------

The outcome variable was self-reported depressive symptoms measured by psychological scales (e.g., the Center for Epidemiologic Studies Depression scale (CES-D), the Patient Health Questionnaire-9 (PHQ-9), the Beck Depression Inventory questionnaire (BDI), the World Health Organization Global School-based Student Health Survey, the Edinburgh Postnatal Depression Scale, the Composite International Diagnostic Interview Short Form scales, the National Institute of Mental Health's Diagnostic Interview Schedule for children Version IV, the Composite International Diagnostic Interview questionnaire), or unstructured questions. Unstructured questions mean that a few unstructured questions were used to measure depressive symptoms (e.g., "During the recent 12 months, have you ever felt sad or hopeless almost every day for two weeks in a row that you stopped doing some usual activities?", or "In the past year, have you felt extremely sorrowful or despair for more than two weeks?"). The main independent variable was SHS exposure measured by self-report or biological tests. SHS exposure was expressed as binary (exposure versus non-exposure), continuous (days/week), or ordinal (e.g., none, 1--4 days/week, or ≥5 days/week) variables.

2.5. Quality Assessment {#sec2dot5-ijerph-16-01356}
-----------------------

For each study retained for meta-analysis, the quality of study design was assessed by the forms for cross-sectional or prevalence study quality of an 11-item checklist \[[@B13-ijerph-16-01356]\]. An item would be scored "0" if it was answered "no" or "unclear"; if it was answered "yes", then the item scored "1". Article quality was assessed as follows: 0--3 for low quality, 4--7 for moderate quality, and 8--11 for high quality.

2.6. Statistical Analysis {#sec2dot6-ijerph-16-01356}
-------------------------

All the statistical analyses were performed using Stata statistical software version 13.0 (StataCorp LP, College Station, Texas, USA). In general, a two-sided *p*-value of \<0.05 was considered as being of statistical significance, except where specified. We generated forest plots for SHS exposure expressed as binary and continuous variables. All the effect estimates were pooled by either fixed-effect models using the method of Mantel and Haenszel (*p* for heterogeneity \>0.1) or random-effect models using the method of DerSimonian and Laird (*p* for heterogeneity ≤0.1) \[[@B14-ijerph-16-01356],[@B15-ijerph-16-01356]\]. Heterogeneity among studies was tested by the chi-squared test with the Cochrane *Q* statistic (significant at *p* ≤0.1) and quantified by *I*^2^ statistic \[[@B16-ijerph-16-01356]\]. In addition, subgroup analyses were performed according to geographical regions, study designs, SHS diagnoses, outcome diagnoses, types of psychological scales, sample sizes, excluding smokers, age groups, sex groups, SHS sources, and adjustment for covariates (e.g., social support, negative life events, and disease history), so as to explore the sources of heterogeneity. Disease history included any history of acute and chronic diseases (e.g., hypertension, diabetes, angina, congestive heart failure, coronary heart disease, heart attack, stroke, asthma, chronic bronchitis, cancer, or other diseases). Publication bias was evaluated by visual inspection of Begg's funnel plot and tested by the Begg's test (significant at *p* ≤ 0.1) \[[@B17-ijerph-16-01356]\].

To derive the dose--response relationship between SHS exposure and depressive symptoms, we carried out dose-response meta-analyses on frequency of SHS exposure expressed as ordinal variables. The dose-response meta-analyses were carried out using linear trend regression and restricted cubic spline regression, choosing the best-fitting model \[[@B18-ijerph-16-01356]\]. Firstly, we used a restricted cubic spline regression model with three knots to create spline variables, and then derived the generalized least squares trend estimation by including spline variables. Secondly, another linear regression model without the spline terms has also been fitted. Lastly, the significance of any non-linearity was examined by the likelihood ratio test that compared the model with the linear term only and the model with both the linear and the cubic spline terms. This analysis used information including the ORs and their corresponding 95% CI, number of cases and non-cases, and median of SHS exposure for each comparison group. For the open-ended upper interval of SHS exposure, we used 1.2-fold its lower limit as its midpoint \[[@B19-ijerph-16-01356]\]. When intervals of SHS exposure categories were reported, the midpoint of the interval was chosen.

3. Results {#sec3-ijerph-16-01356}
==========

3.1. Characteristics of Studies {#sec3dot1-ijerph-16-01356}
-------------------------------

The literature search and study selection process were shown in [Figure 1](#ijerph-16-01356-f001){ref-type="fig"}. After excluding studies that did not meet the inclusion criteria, 24 studies were included in the present meta-analysis \[[@B7-ijerph-16-01356],[@B8-ijerph-16-01356],[@B9-ijerph-16-01356],[@B10-ijerph-16-01356],[@B20-ijerph-16-01356],[@B21-ijerph-16-01356],[@B22-ijerph-16-01356],[@B23-ijerph-16-01356],[@B24-ijerph-16-01356],[@B25-ijerph-16-01356],[@B26-ijerph-16-01356],[@B27-ijerph-16-01356],[@B28-ijerph-16-01356],[@B29-ijerph-16-01356],[@B30-ijerph-16-01356],[@B31-ijerph-16-01356],[@B32-ijerph-16-01356],[@B33-ijerph-16-01356],[@B34-ijerph-16-01356],[@B35-ijerph-16-01356],[@B36-ijerph-16-01356],[@B37-ijerph-16-01356],[@B38-ijerph-16-01356],[@B39-ijerph-16-01356]\], including 22 cross-sectional studies and two cohort studies. All the study participants were from the healthy population, rather than the clinical population. The main characteristics and findings of these studies on SHS exposure and depressive symptoms are given in [Table 1](#ijerph-16-01356-t001){ref-type="table"}. Sixteen of these studies were conducted in Asia, seven were conducted in the United States (USA), and one was conducted in Europe. In terms of SHS exposure, 24 studies reported the binary exposure (exposure versus non-exposure) and 11 reported the frequency of exposure. The quality score of each study was presented in [Table 1](#ijerph-16-01356-t001){ref-type="table"}. Six studies were of high quality, 18 studies were of moderate quality, and no study was of low quality.

3.2. Relationship between Binary SHS Exposure and Depressive Symptoms {#sec3dot2-ijerph-16-01356}
---------------------------------------------------------------------

The overall OR of depressive symptoms comparing SHS exposure with non-exposure was presented in [Figure 2](#ijerph-16-01356-f002){ref-type="fig"}. An overall 32% increase in the odds of depressive symptoms was observed for SHS exposure (OR = 1.32, 95% CI 1.25--1.39), and some heterogeneity was observed (*I*^2^ = 72.6%, *p* \< 0.001). Therefore, we carried out stratified analyses to assess the heterogeneity across subgroups ([Table 2](#ijerph-16-01356-t002){ref-type="table"}). As to SHS diagnoses, the relation was significantly stronger (*p* for differences between subgroups \<0.001) in studies using self-reported SHS (OR = 1.34, 95% CI = 1.27--1.41) than in those using biological SHS (OR = 1.11, 95% CI = 1.04--1.17), indicating that using self-reported SHS may overestimate the adverse relation. As to outcome diagnoses, the relation was significantly stronger (*p* for differences between subgroups = 0.037) in studies using psychological scales (OR = 1.45, 95% CI = 1.29--1.61) than in those using unstructured questions (OR = 1.27, 95% CI = 1.21--1.32), indicating that using unstructured questions may underestimate the adverse relation. As to types of psychological scales, there were significant differences in OR estimates (OR = 1.67, 95% CI = 1.35--1.99, for CES-D scales; OR = 1.30, 95% CI = 1.09--1.51, for BDI scales; OR = 1.10, 95% CI = 1.03--1.16, for PHQ-9, OR = 1.29, 95% CI = 1.24--1.35, for others; *P* for differences between subgroups = 0.001), indicating that using the CES-D may overestimate the adverse relation. When doing subgroup analyses on adjustment for covariates, significant differences were observed between adjusted and unadjusted ORs for social support (OR = 1.84 versus OR = 1.28, *p* for differences between subgroups \< 0.001), negative life events (OR = 1.67 versus OR = 1.28, *p* for differences between subgroups = 0.040) and disease history (OR = 1.37 versus OR = 1.25, *p* for differences between subgroups = 0.070), suggesting that non-adjustment for these covariates may underestimate the adverse relation. However, there were non-significant differences between subgroups according to study locations (*p* = 0.539), study designs (*p* = 0.524), sample sizes (*p* = 0.651), excluding smokers (*p* = 0.183), age groups (*p* = 0.394), sex groups (*p* = 0.370), SHS sources (*p* = 0.426), and adjustment for disease history (*p* = 0.070). No publication bias was observed from visual inspection of the funnel plot and from the Begg's test (*p* = 0.385), indicating that SHS exposure was consistently associated with increased odds of depressive symptoms.

3.3. Relationship between SHS Exposure Expressed as a Continuous Variable and Depressive Symptoms {#sec3dot3-ijerph-16-01356}
-------------------------------------------------------------------------------------------------

When SHS exposure was expressed as a continuous variable (days/week), the relationship between continuous days of SHS exposure and depressive symptoms was presented in [Figure 3](#ijerph-16-01356-f003){ref-type="fig"}. The overall OR for having depressive symptoms increased with increasing days of SHS exposure (OR = 1.57, 95% CI = 1.26--1.87), indicating that the odds for having depressive symptoms increased with every one-day increment in SHS exposure. In addition, some heterogeneity was observed (*I*^2^ = 86.8%, *p* \< 0.001). Therefore, we carried out stratified analyses to assess the heterogeneity across subgroups defined by sex groups, age groups, and SHS sources. In terms of SHS sources, there were significant differences in the odds of depressive symptoms (OR = 2.30, 95% CI = 1.74--2.86, for campuses; OR = 1.74, 95% CI = 1.26--2.23, for public places; OR = 1.47, 95% CI = 1.15--1.78, for workplaces; OR = 1.30, 95% CI = 0.97--1.62, for homes; *p* for differences between subgroups = 0.019). However, there were non-significant differences between studies in different sex groups (OR = 1.00, 95% CI = 0.97--1.03, for males; OR = 1.22, 95% CI = 0.87--1.56, for females; *p* for differences between subgroups = 0.213) and age groups (OR = 1.39, 95% CI = 1.21--1.56, for adults; OR = 1.24, 95% CI = 0.74--1.75, for adolescents; *p* for differences between subgroups *=* 0.582). No publication bias was observed from visual inspection of the funnel plot and from the Begg's test (*p* = 0.917), indicating that days of SHS exposure was consistently associated with increased odds of depressive symptoms.

3.4. Relationship between SHS Exposure Expressed as Ordinal Variables and Depressive Symptoms {#sec3dot4-ijerph-16-01356}
---------------------------------------------------------------------------------------------

When hours of SHS exposure per day were expressed as ordinal variables ([Table 3](#ijerph-16-01356-t003){ref-type="table"}), the dose--response meta-analysis model revealed a linear relationship between hours of SHS exposure and odds of depressive symptoms (*p* for linear trend \<0.001; [Figure 4](#ijerph-16-01356-f004){ref-type="fig"}A). A monotonically increasing relationship was consistently observed for hours of SHS exposure (OR = 1.09 for half-hour per day; OR = 1.19 for one hour per day; OR = 1.42 for two hours per day; OR = 1.70 for three hours per day).

When days of SHS exposure per week were expressed as ordinal variables ([Table 4](#ijerph-16-01356-t004){ref-type="table"}), the dose--response meta-analysis model revealed a non-linear relationship between days of SHS exposure and depressive symptoms (*p* for non-linear trend \<0.001; [Figure 4](#ijerph-16-01356-f004){ref-type="fig"}B). A monotonically increasing relationship was observed for days of SHS exposure (OR = 1.09 for one day per week; OR = 1.19 for two days per week; OR = 1.26 for three days per week; OR = 1.32 for four days per week; OR = 1.38 for five days per week; OR = 1.42 for six days per week).

4. Discussion {#sec4-ijerph-16-01356}
=============

The present meta-analysis included more new studies to confirm the positive association between binary SHS exposure and depressive symptoms (OR = 1.32, 95% CI 1.25--1.39). In addition, this study contributes to the literature by finding a monotonically increasing dose--response relationship between SHS exposure expressed as an ordinal variable and odds of depressive symptoms. A similar dose--response relationship was observed for SHS exposure expressed as a continuous variable (OR = 1.57, 95% CI = 1.26--1.87).

Increasing epidemiological studies have focused on studying the potential association between SHS exposure and depressive symptoms, but the findings are inconsistent. For example, recent evidence revealed that SHS exposure was significantly associated with higher rates of depressive symptoms \[[@B7-ijerph-16-01356],[@B8-ijerph-16-01356],[@B24-ijerph-16-01356],[@B29-ijerph-16-01356]\], but a non-significant relation was found in other studies \[[@B9-ijerph-16-01356],[@B10-ijerph-16-01356]\]. Evidence from this updated meta-analysis of 24 observational studies revealed that an overall 32% increase in the odds of depressive symptoms was observed for SHS exposure (OR = 1.32, 95% CI 1.25--1.39). This finding is consistent with the only meta-analysis in the past, which only included seven observational studies and reported a 60% increase in the prevalence of depressive symptoms for SHS exposure (OR = 1.60, 95% CI 1.35--1.90) \[[@B11-ijerph-16-01356]\]. Notably, only two prospective studies were conducted in the past 10 years, which may reduce the power of revealing the association between SHS exposure and depressive symptoms. Therefore, more longitudinal studies are needed to address the causal link in the future. Notably, as to the relationships for SHS exposure expressed as a continuous variable (days/week) based on four studies, the stratified analysis revealed that there were significant differences in the OR estimates between subgroups according to SHS sources (*p* for differences between subgroups = 0.019). However, as to the relationships for binary SHS exposure based on 24 studies, the stratified analysis found that there were non-significant differences in the OR estimates between subgroups according to SHS sources (*p* = 0.426). The above inconsistent results on exposure-specific association may be due to differences in the number of included studies, measurement methods for SHS (self-report or cotinine level) and depressive symptoms (psychological scales or unstructured questions), prevalence rates of SHS exposure and depressive symptoms, and so on.

The most important question remains unclear, and that is the dose--response relationship between SHS exposure and depressive symptoms. Some recent studies revealed linear trends between SHS exposure and depressive symptoms \[[@B7-ijerph-16-01356],[@B22-ijerph-16-01356],[@B24-ijerph-16-01356]\], but non-significant associations were observed in other studies \[[@B25-ijerph-16-01356],[@B31-ijerph-16-01356]\], suggesting that these findings are inconsistent. To the best of our knowledge, there is still no meta-analysis available to explore this dose--response relationship. A novel aspect of this study is to clarify the potential dose--response relationship, so a dose--response meta-analysis was performed for SHS exposure expressed as an ordinal variable. An important finding is that there is a linear relationship for hours of SHS exposure (*p* for linear trend \< 0.001) and a non-linear relationship for days of SHS exposure (*p* for non-linear trend \< 0.001), indicating a monotonically increasing trend for SHS exposure. Additionally, when SHS exposure was expressed as a continuous variable (days/week), the odds for having depressive symptoms increased with increasing days of SHS exposure (OR = 1.57, 95% CI = 1.26--1.87), which may provide more evidence for potential dose-response relationships. Notably, previous studies only focused on the linear model to explore above dose-response relationship, and none have reported these relationships based on non-linear models. Our findings suggest that future studies should focus on both linear and non-linear models to reveal the potential relationship.

Some methodological limitations and uncontrolled variables in the included studies may contribute to the heterogeneity between studies. First, most of the studies included in this meta-analysis used self-reported questionnaires instead of a more accurate biological measure to confirm SHS exposure, resulting in an underestimation or overestimation of the true association. Consistent with the previous meta-analysis \[[@B11-ijerph-16-01356]\], the subgroup analysis stratified by SHS diagnosis revealed that the adverse relation was significantly stronger in studies using self-reported SHS than in those using biological SHS, indicating that using self-reported SHS may overestimate the odds of depressive symptoms. However, for studies with the cross-sectional design, there is a possibility that study participants with higher levels of depressive symptoms may tend to report more SHS exposure. Therefore, results from this study need to be confirmed in future meta-analyses including more longitudinal studies. Second, although most of the depression scales have high reliability and validity \[[@B40-ijerph-16-01356],[@B41-ijerph-16-01356],[@B42-ijerph-16-01356]\], the different diagnosis methods for depressive symptoms applied in the studies may have resulted in biases in pooled estimates. Our subgroup analysis by outcome diagnosis indicated that the adverse association was significantly stronger in studies using psychological scales than in those using unstructured questions, indicating that using unstructured questions may underestimate the odds of depressive symptoms. Third, other covariates may have potential influences on effect estimates. Our subgroup analyses revealed that there were significant differences between adjusted and unadjusted ORs for social support and negative life events, suggesting that non-adjustment for these covariates may underestimate the association between SHS exposure and depressive symptoms.

There are several behavioral and biological mechanisms that may explain the relationship between SHS exposure and depressive symptoms. First, SHS exposure may be an indicator of stressful working and living environments, which in turn may lead to depressive symptoms or depression \[[@B43-ijerph-16-01356],[@B44-ijerph-16-01356]\]. Second, SHS exposure has been associated with adverse health effects. All of the adverse effects (such as cancer, respiratory disease, and so on) in turn may cause depressive symptoms by direct and indirect multi-step process \[[@B6-ijerph-16-01356],[@B45-ijerph-16-01356]\]. Third, SHS exposure may contribute to lowering levels of dopamine and γ-aminobutyric acid, which have been related to an increased risk for depressive symptoms as observed in firsthand smokers \[[@B46-ijerph-16-01356],[@B47-ijerph-16-01356]\]. Finally, the adverse effect of SHS exposure has been attributed to the inflammation-associated mechanism. SHS exposure may induce the body to produce inflammatory cytokines, which can contribute directly to the development of depressive symptoms \[[@B48-ijerph-16-01356],[@B49-ijerph-16-01356]\].

A novel aspect of this study is that the information on continuous and ordinal frequency of SHS exposure was considered in order to better understand the dose--response relationship. However, there are some potential limitations to this study. First, because of resource limitations, this study did not include some unpublished studies, which may bring some publication bias. However, the likelihood should be small, since the funnel plot and Begg's test indicated no evidence of publication bias among all the studies included in this meta-analysis. Second, although it is very meaningful to explore the potential dose--response relationships on dose or duration of SHS exposure, there are not sufficient data on dose and duration of SHS exposure to carry out such dose--response meta-analyses. Third, a relatively small sample size of longitudinal studies may have limited our power of revealing the association between exposure and outcomes. Therefore, more longitudinal studies are needed to address their causality.

5. Conclusions {#sec5-ijerph-16-01356}
==============

This meta-analysis confirms that SHS exposure is positively associated with odds of depressive symptoms. Additionally, this study adds to existing knowledge by finding linear and non-linear dose--response relationships between SHS exposure and depressive symptoms. These findings highlight the significance of reducing SHS exposure worldwide, and more longitudinal studies are needed to establish the causal relationship in the future.

X.Y., J.Z., C.H., and Y.L. conceived and designed the study; C.H. and Y.L. collected the data; X.G., C.H. and Y.L. analyzed the data, X.Y., J.Z., C.H. and Y.L. wrote the paper; and all the co-authors participated in the revising of the manuscript and approved the version submitted for publication.

This study was supported by the Medical Scientific Research Foundation of Guangdong Province, China (No. A2017036). The funders had no role in study design, data collection and analysis, or interpretation of the data.

All authors declare that they have no conflict of interest regarding the publication of this paper.

![Flowchart of literature search and study selection.](ijerph-16-01356-g001){#ijerph-16-01356-f001}
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ijerph-16-01356-t001_Table 1

###### 

Main characteristics of studies in the meta-analysis.

  Author           Location   Design   Outcome Diagnosis       SHS Diagnosis   *n*       OR (95% CI)         Quality Score
  ---------------- ---------- -------- ----------------------- --------------- --------- ------------------- ---------------
  Nakata-2008      Asia       CS       scale                   BT              2770      1.75 (1.20--2.30)   6
  Bandiera-2010    USA        CS       scale                   BT              2965      1.09 (1.03--1.16)   6
  Bandiera-2011    USA        CS       scale                   BT              2901      1.25 (1.06--1.46)   7
  Tan-2011         USA        CS       scale                   SR              929       2.50 (1.20--5.20)   6
  Michal-2013      Europe     CS       scale                   SR              5000      1.12 (0.75--1.49)   6
  Lee-2014         Asia       CS       unstructured question   SR              75,643    1.25 (1.21--1.29)   8
  Taha-2014        USA        CS       scale                   SR              2101      1.70 (1.10--2.50)   8
  Elmasry-2014     USA        cohort   scale                   SR              178       1.69 (0.73--3.93)   6
  Jung-2015        Asia       CS       unstructured question   SR              34,693    1.13 (0.92--1.33)   7
  Kim-2015         Asia       CS       scale                   SR              1201      1.70 (1.23--2.36)   7
  Khan-2015        USA        CS       unstructured question   SR              6884      1.49 (1.23--1.80)   6
  Ye-2015          Asia       CS       scale                   SR              1280      2.04 (1.48--2.79)   8
  Bauer-2015       Asia       CS       scale                   SR              2441      2.00 (0.60--6.80)   6
  Leung-2015       Asia       cohort   scale                   SR              7914      1.48 (0.98--2.23)   7
  Kelishadi-2015   Asia       CS       scale                   SR              13,486    1.37 (1.24--1.51)   7
  Weng-2016        Asia       CS       scale                   SR              3867      1.76 (1.47--2.11)   6
  Kim-2016a        Asia       CS       unstructured question   SR              123,665   1.25 (1.16--1.33)   8
  Kim-2016b        Asia       CS       scale                   SR              989       1.22 (1.02--1.47)   8
  Bang-2017        Asia       CS       unstructured question   BT              62,708    1.34 (1.29--1.40)   7
  Park-2017        Asia       CS       unstructured question   SR              56,840    1.22 (1.16--1.28)   7
  Huang-2017       Asia       CS       scale                   SR              2176      2.22 (1.12--4.39)   8
  Kawasaki-2017    Asia       CS       scale                   SR              1745      1.27 (1.04--1.54)   7
  Huang-2018       Asia       CS       scale                   SR              3575      1.79 (1.54--2.08)   7
  Patten-2018      USA        CS       scale                   SR              184,305   1.70 (1.50--6.80)   7

Note: *n*, number of participants; OR, odds ratio; CS, cross-sectional; SHS, secondhand smoke; SR, self-reported; BT, biological test.

ijerph-16-01356-t002_Table 2

###### 

Pooled ORs of depressive symptoms in strata of selected covariates.

  Subgroups                                                   No. of Studies      OR (95% CI)         Statistical Method   *p*-Value for Heterogeneity ^b^
  ------------------------------------- --------------------- ------------------- ------------------- -------------------- ---------------------------------
  All studies                                                 24                  1.32 (1.25--1.39)   random               
  Location                              Asia                  16                  1.33 (1.26--1.40)   random               0.539
                                        USA                   7                   1.30 (1.09--1.51)   random               
                                        Europe                1                   1.12 (0.75--1.49)   fixed                
  Study design                          cross-sectional       22                  1.32 (1.25--1.39)   random               0.524
                                        cohort                2                   1.51 (0.93--2.09)   fixed                
  SHS diagnosis                         self-report           22                  1.34 (1.27--1.41)   random               \<0.001
                                        biological test       2                   1.11 (1.04--1.17)   fixed                
  Outcome diagnosis                     psychological scale   18                  1.45 (1.29--1.61)   random               0.037
  unstructured question                 6                     1.27 (1.21--1.32)   random                                   
  Types of psychological scales         CES-D                 6                   1.67 (1.35--1.99)   random               \<0.001
                                        PHQ-9                 3                   1.10 (1.03--1.16)   fixed                
                                        BDI                   3                   1.30 (1.09--1.51)   fixed                
                                        Others ^a^            12                  1.29 (1.24--1.35)   random               
  Sample size                           \>500                 23                  1.32 (1.25--1.39)   random               0.651
                                        ≤500                  1                   1.69 (0.73--3.93)   fixed                
  Excluding smokers                     Yes                   16                  1.33 (1.23--1.42)   random               0.183
  No                                    8                     1.26 (1.22--1.30)   random                                   
  Age group                             adolescent            9                   1.31 (1.24--1.38)   random               0.394
                                        adult                 14                  1.38 (1.23--1.52)   random               
  Sex group                             female                14                  1.28 (1.20--1.35)   random               0.370
                                        male                  6                   1.24 (1.20--1.29)   fixed                
  SHS source                            home                  18                  1.30 (1.24--1.35)   random               0.426
                                        workplace             5                   1.53 (1.03--2.02)   random               
                                        public place          3                   1.44 (1.26--1.63)   fixed                
                                        campus                2                   1.32 (1.25--1.38)   random               
  Adjustment for social support                                                                                            
                                        yes                   3                   1.84 (1.59--2.08)   fixed                \<0.001
                                        no                    21                  1.28 (1.22--1.34)   random               
  Adjustment for negative life events                                                                                      
                                        yes                   6                   1.67 (1.31--2.04)   random               0.040
                                        no                    18                  1.28 (1.21--1.36)   random               
  Adjustment for disease history                                                                                           
                                        yes                   11                  1.37 (1.24--1.49)   random               0.070
                                        no                    13                  1.25 (1.22--1.29)   fixed                

Notes: BDI, Beck Depression Inventory questionnaire; CES-D, Center for Epidemiologic Studies Depression scale; OR, odd ratios; PHQ-9, Patient Health Questionnaire-9; SHS, secondhand smoke; ^a^ Others included the World Health Organization Global School-based Student Health Survey, the Edinburgh Postnatal Depression Scale, the Composite International Diagnostic Interview Short Form scales, the National Institute of Mental Health's Diagnostic Interview Schedule for children Version IV, the Composite International Diagnostic Interview questionnaire, or unstructured questions. ^b^ Chi-squared test was used to test the heterogeneity between subgroups.
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###### 

Epidemiological studies of frequency of SHS exposure (hours/day) and depressive symptoms.

  Author               SHS Source   SHS Frequency (Hours/Day)   Midpoint Frequency (Hours/Day) ^a^   OR (95% CI)
  -------------------- ------------ --------------------------- ------------------------------------ -------------------
  Jung-2015 (male)     workplace    0                           0                                    1.00
                                    \<1                         0.5                                  0.92 (0.77--1.09)
                                    ≥1                          1.2                                  1.23 (0.97--1.54)
  Jung-2015 (female)   workplace    0                           0                                    1.00
                                    \<1                         0.5                                  0.89 (0.76--1.04)
                                    ≥1                          1.2                                  1.32 (1.06--1.64)
  Jung-2015 (male)     home         0                           0                                    1.00
                                    \<1                         0.5                                  0.90 (0.65--1.23)
                                    ≥1                          1.2                                  1.21 (0.69--2.13)
  Jung-2015 (female)   home         0                           0                                    1.00
                                    \<1                         0.5                                  1.18 (1.02--1.35)
                                    ≥1                          1.2                                  1.71 (1.34--2.18)
  Kim-2016 (male)      home         0                           0                                    1.00
                                    \<1                         0.5                                  0.99 (0.66--1.48)
                                    1--2.9                      2.0                                  2.01 (1.04--3.86)
                                    ≥3                          3.6                                  1.87 (1.43--2.44)
  Kim-2016 (female)    home         0                           0                                    1.00
                                    \<1                         0.5                                  0.98 (0.87--1.11)
                                    1--2.9                      2.0                                  1.37 (1.07--1.75)
                                    ≥3                          3.6                                  1.56 (1.42--1.72)

Notes: OR, odds ratio; SHS, secondhand smoke; ^a^ When intervals of aspirin categories were reported, the midpoint of the interval was chosen; for the open-ended upper interval, we used 1.2-fold its lower limit.
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###### 

Epidemiological studies of frequency of SHS exposure (days/week) and depressive symptoms.

  Author       SHS Source       SHS Frequency (Days/Week)   Midpoint Frequency (Days/Week) ^a^   OR (95% CI)
  ------------ ---------------- --------------------------- ------------------------------------ -------------------
  Lee-2015     home             0                           0                                    1.00
                                1--4                        2.5                                  1.22 (1.17--1.27)
                                ≥5                          6.0                                  1.36 (1.29--1.43)
  Ye-2015      home             0                           0                                    1.00
                                1--3                        2.0                                  2.12 (1.41--3.21)
                                4--7                        5.5                                  2.53 (1.70--3.78)
  Ye-2015      workplace        0                           0                                    1.00
                                1--3                        2.0                                  2.08 (1.25--3.45)
                                4--7                        5.5                                  2.58 (1.16--3.73)
  Huang-2017   home             0                           0                                    1.00
                                1--3                        2.0                                  1.73 (0.66--4.49)
                                4--7                        5.5                                  2.36 (1.09--5.13)
  Huang-2017   workplace        0                           0                                    1.00
                                1--3                        2.0                                  1.42 (0.31--6.54)
                                4--7                        5.5                                  3.19 (1.17--8.74)
  Huang-2018   public place     0                           0                                    1.00
                                1--4                        2.5                                  1.28 (1.06--1.53)
                                5--7                        6.0                                  1.66 (1.30--2.10)
  Huang-2018   home             0                           0                                    1.00
                                1--4                        2.5                                  0.98 (0.78--1.24)
                                5--7                        6.0                                  1.50 (1.22--1.85)
  Huang-2018   indoor campus    0                           0                                    1.00
                                1--4                        2.5                                  1.36 (1.08--1.71)
                                5--7                        6.0                                  2.13 (1.56--2.91)
  Huang-2018   outdoor campus   0                           0                                    1.00
                                1--4                        2.5                                  1.37 (1.11--1.68)
                                5--7                        6.0                                  1.83 (1.38--2.44)

Note: OR, odds ratio; SHS, secondhand smoke. ^a^ When intervals of aspirin categories were reported, the midpoint of the interval was chosen; for the open-ended upper interval, we used 1.2-fold its lower limit.
